Lantern Pharma Stock Forum

$Lantern Pharma (LTRN.US)$ Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients

$China Pharma (CPHI.US)$ $Bright Minds Biosciences (DRUG.US)$ $Lantern Pharma (LTRN.US)$ $Cytosorbents (CTSO.US)$ $Intensity Therapeutics (INTS.US)$ $Multi Ways (MWG.US)$ $Salarius Pharmaceuticals (SLRX.US)$ $X3 Holdings (XTKG.US)$ $Protagenic Therapeutics (PTIX.US)$ $GRI Bio (GRI.US)$ $Paranovus Entertainment Technology (PAVS.US)$ $VSee Health (VSEE.US)$
📊⚡️📊

$Lantern Pharma (LTRN.US)$ Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
6 MINUTES AGO, 9:07 AM EDT
VIA BUSINESSWIRE

$Lantern Pharma (LTRN.US)$
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's Cancers
• Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma.
• This brings the total number of RPDDs for LP-184 to 4, including one previously granted for ATRT (Atypical Teratoid Rhabdoid Tumors)....

$Lantern Pharma (LTRN.US)$ This possible play is purely chart driven! Thats the reason im sharing. So those that asked. Here is a example of some of what i look for. This is what brought my attention here🤔🤫

$Lantern Pharma (LTRN.US)$
Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024
Lantern Pharma (NASDAQ: LTRN) announced promising preclinical results for LP-184, demonstrating synergy with checkpoint inhibitors and the ability to resensitize tumors non-responsive to Anti-PD1 therapies. Key findings include:
1. LP-18...

$Lantern Pharma (LTRN.US)$
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
Lantern Pharma (NASDAQ: LTRN) has achieved a milestone in developing a qRT-PCR-based diagnostic for its drug candidate, LP-184. This diagnostic quantifies PTGR1 RNA in tumor samples, helping identify patients likely to respond to LP-184 across various solid tumors. Successful confirm...

$Lantern Pharma (LTRN.US)$
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284